AMWL — American Well Corporation

Is AMWL overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Health Information Services

Oversold As of November 17, 2026

American Well Corporation (AMWL) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Health Information Services) last closed at $11.20. The rating moved from Strong Oversold to Oversold on November 9, 2026.

See all oversold Healthcare stocks →

AI analysis

American Well is positioned in a growing telehealth market with established enterprise relationships that can drive recurring revenue as virtual care normalizes. Revenue upside hinges on scaling payer and health-system deployments and improving service economics; however, the company has historically operated at a loss and needs to demonstrate durable margin improvement and cash-flow progress. Near-term catalysts include expanded enterprise contracts, product monetization across chronic care and specialty channels, and execution on cost structure. Key challenges are regulatory headwinds around Medicare program integrity, aggressive competition from incumbents and integrated care players, and execution/financing risk if growth stalls. Given mixed visible catalysts and elevated execution and regulatory risks, a measured stance is warranted while monitoring upcoming operational results and any material contract announcements.

Key factors

  • Market position as a leading telehealth platform with enterprise relationships (providers, payors, health systems) supporting recurring revenue opportunities
  • Revenue growth driven by expanded virtual care adoption, chronic care management and partnerships with health systems and retailers
  • Ongoing margin pressure and historical net losses; path to profitability depends on scaling enterprise contracts and improving service margins
  • Regulatory environment in healthcare (notably Medicare Advantage integrity measures) could affect reimbursement models and partner economics
  • Competitive landscape includes large incumbents and vertically integrated healthcare players that can pressure pricing and share
  • Macro/market backdrop showing measured risk-on tone and selective support for growth names, which may help near-term sentiment but not fundamentals
  • Limited public filing / social-sentiment signals in the provided data set reduce near-term visibility into catalyst timing

Risks

  • Increased regulatory scrutiny of Medicare/Medicaid (RADV/anti-billing measures) that could reduce utilization or reimbursement for virtual care services
  • Intense competition from Teladoc, large health systems, payors, and tech platforms leading to pricing pressure and client churn
  • Execution risk around converting pilots to scaled enterprise deployments and maintaining retention of large customers
  • Cash burn and financing risk if revenue growth slows before profitability or positive free cash flow is achieved
  • Dependence on third-party integrations and partners; operational/technical outages could harm reputation and contracts
  • Limited near-term visibility from absent recent filings or social/research signals in the dataset
  • Potential concentration risk if a small number of customers account for a large share of revenue

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for AMWL — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.